Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Guj Themis Biosyn
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel

Guj. Themis Biosyn

WEBSITE BSE:506879 NSE: GUJ.THEMIS. Inc. Year: 1981 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock

₹382.8 9.8 | 2.6%

Last updated: 15:57

Consolidated Standalone

Last updated: 15:57

My Notes

No Notes Added Yet

Guj. Themis Biosyn Overview

Gujarat Themis Biosyn Ltd is engaged in the production of pharmaceuticals and medicinal chemical merchandise. The Company's R&D division makes a speciality on developing fermentation cultures. The Company's products consist of Rifamycin-S, that is an intermediate for Rifampicin for the remedy of tuberculosis (TB), and Lovastatin. It is engaged in manufacturing bulk drugs. The Company's plant is located at Valsad, Gujarat.

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Guj. Themis Biosyn Key Financials

Market Cap ₹4171 Cr.

Stock P/E 85.5

P/B 15.1

Current Price ₹382.8

Book Value ₹ 25.4

Face Value 1

52W High ₹479.5

Dividend Yield 0.18%

52W Low ₹ 225.8

Edit Ratio

Guj. Themis Biosyn Share Price

₹ | |

Volume
Price

Guj. Themis Biosyn Quarterly Price

Quarterly Monthly
Show Value Show %

Guj. Themis Biosyn Peer Comparison

Guj. Themis Biosyn Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 40 39 42 39 35 40 38 36 42 43
Other Income 1 1 1 1 0 0 1 0 1 0
Total Income 41 40 43 39 35 40 39 36 43 44
Total Expenditure 23 21 21 20 19 21 22 22 21 22
Operating Profit 18 19 22 19 16 19 17 14 22 22
Interest 0 0 0 0 0 0 0 0 0 1
Depreciation 1 1 1 1 1 2 1 2 3 4
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 17 18 21 18 14 17 16 12 19 17
Provision for Tax 4 5 5 5 4 4 4 3 4 4
Profit After Tax 13 13 16 13 11 13 12 9 14 12
Adjustments 0 0 0 -0 -0 -0 0 0 -0 0
Profit After Adjustments 13 13 16 13 11 13 12 9 14 12
Adjusted Earnings Per Share 1.2 1.2 1.5 1.2 1 1.2 1.1 0.8 1.3 1.1

Guj. Themis Biosyn Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 31 33 36 39 41 85 91 115 148 170 151 159
Other Income 0 0 0 0 2 2 3 4 7 4 2 2
Total Income 32 33 36 39 43 87 94 119 155 174 153 162
Total Expenditure 25 27 30 33 34 53 50 57 75 91 82 87
Operating Profit 6 6 6 6 10 34 44 62 80 83 71 75
Interest 0 0 0 0 0 1 1 1 0 0 0 1
Depreciation 1 1 1 1 1 1 2 2 3 4 5 10
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 5 5 5 5 8 31 41 59 77 79 66 64
Provision for Tax 0 0 1 1 2 8 11 15 19 20 17 15
Profit After Tax 5 5 4 4 6 24 30 44 58 59 49 47
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 5 5 4 4 6 24 30 44 58 59 49 47
Adjusted Earnings Per Share 0.4 0.4 0.4 0.4 0.6 2.2 2.8 4 5.3 5.4 4.5 4.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -11% 10% 12% 17%
Operating Profit CAGR -14% 5% 16% 28%
PAT CAGR -17% 4% 15% 26%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 40% 56% 62% 50%
ROE Average 22% 34% 41% 67%
ROCE Average 27% 45% 54% 63%

Guj. Themis Biosyn Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds -1 4 8 12 19 42 70 103 149 201 248
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 5 1 1 0 0 3 0 0 0 0 30
Other Non-Current Liabilities 0 0 1 0 1 1 2 2 2 4 3
Total Current Liabilities 10 9 12 8 13 24 26 32 36 36 37
Total Liabilities 15 15 21 20 33 71 98 137 187 241 318
Fixed Assets 10 9 11 11 15 17 19 19 33 38 41
Other Non-Current Assets 2 2 3 2 10 18 6 25 72 136 208
Total Current Assets 3 3 8 8 8 36 73 93 82 68 69
Total Assets 15 15 21 20 33 71 98 137 187 241 318

Guj. Themis Biosyn Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 0 0 0 1 1 1 4 0 6 6
Cash Flow from Operating Activities 3 4 3 6 1 1 11 40 39 64 91
Cash Flow from Investing Activities -0 -1 -3 -1 -6 -3 -2 -30 -20 -55 -112
Cash Flow from Financing Activities -3 -3 -0 -4 5 2 -5 -14 -13 -9 26
Net Cash Inflow / Outflow -1 -0 0 1 0 -0 3 -4 6 0 5
Closing Cash & Cash Equivalent 0 0 0 1 1 1 4 0 6 6 12

Guj. Themis Biosyn Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.42 0.42 0.4 0.35 0.59 2.17 2.77 4 5.32 5.43 4.48
CEPS(Rs) 0.55 0.53 0.5 0.46 0.7 2.3 2.93 4.21 5.56 5.75 4.97
DPS(Rs) 0 0 0 0 0 0.22 0 1.47 0.72 0.67 0.67
Book NAV/Share(Rs) -0.07 0.35 0.75 1.11 1.7 3.87 6.42 9.48 13.69 18.48 22.79
Core EBITDA Margin(%) 19.94 18.5 16.95 16.08 17.93 37.4 44.53 50.54 49.62 46.36 45.65
EBIT Margin(%) 15.84 15.35 14.83 13.55 20.35 37.8 46.23 52.12 52.32 46.85 43.7
Pre Tax Margin(%) 14.61 14.19 13.69 12.47 19.97 36.72 45.14 51.4 52.21 46.72 43.46
PAT Margin (%) 14.61 14.19 12.26 9.97 15.61 27.81 33.32 37.98 39.07 34.84 32.34
Cash Profit Margin (%) 18.99 17.86 15.4 12.93 18.59 29.41 35.24 39.93 40.8 36.92 35.91
ROA(%) 29.88 31.5 24.25 18.45 24.07 45.62 35.65 37.08 35.81 27.65 17.44
ROE(%) 0 302.71 72.63 38.06 41.85 77.99 53.82 50.35 45.92 33.76 21.69
ROCE(%) 113.74 80.38 54.67 42.22 44.88 85.96 67.89 67.91 61.51 45.4 27.48
Receivable days 20.96 25.38 46.8 45.67 37.88 55.8 70.42 63.29 52.91 48.29 70.51
Inventory Days 4.57 4.19 4.73 4.57 3.55 13.65 24.34 28.06 32.26 19.29 10.13
Payable days 0 0 2000.09 1308.78 2103.6 215.31 132.5 115.1 114.42 99.37 193.03
PER(x) 11.99 15.94 17.21 15.67 8.91 5.96 9.8 13.57 17.2 48.64 62.89
Price/Book(x) -70.11 19.2 9.18 5 3.08 3.35 4.23 5.73 6.69 14.29 12.35
Dividend Yield(%) 0 0 0 0 0 1.7 0 2.7 0.79 0.25 0.24
EV/Net Sales(x) 1.94 2.36 2.21 1.46 1.5 1.73 3 5.05 6.66 16.9 20.46
EV/Core EBITDA(x) 9.58 12.4 12.31 8.86 6.41 4.39 6.22 9.33 12.32 34.53 43.28
Net Sales Growth(%) 4 3.77 9.4 8.71 5.8 107.37 6.39 26.82 29.19 14.45 -11.2
EBIT Growth(%) -4.95 0.51 5.72 -0.71 58.95 285.2 30.09 42.99 29.7 2.48 -17.17
PAT Growth(%) 1.51 0.77 -5.44 -11.66 65.73 269.4 27.48 44.55 32.88 2.06 -17.56
EPS Growth(%) 1.49 0.78 -5.45 -11.65 65.74 269.4 27.47 44.55 32.88 2.06 -17.56
Debt/Equity(x) -7.74 0.86 0.49 0.05 0.32 0.19 0.04 0 0 0 0.12
Current Ratio(x) 0.35 0.34 0.69 0.99 0.63 1.49 2.84 2.93 2.3 1.87 1.84
Quick Ratio(x) 0.32 0.32 0.65 0.93 0.6 1.24 2.6 2.57 1.89 1.78 1.71
Interest Cover(x) 12.86 13.26 12.96 12.59 52.71 34.85 42.66 72.31 440.64 347.14 181.05
Total Debt/Mcap(x) 0.11 0.05 0.05 0.01 0.11 0.06 0.01 0 0 0 0.01

Guj. Themis Biosyn Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 70.86 70.86 70.86 70.86 70.86 70.86 70.86 70.86 70.86 70.86
FII 0.87 1.05 1.44 1.49 1.42 1.91 2.51 2.95 1.96 1.8
DII 0.04 0.82 1.18 1.17 1.18 1.18 1.18 1.18 1.18 1.18
Public 28.23 27.26 26.51 26.47 26.54 26.05 25.45 25.01 26 26.16
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Guj. Themis Biosyn News

Guj. Themis Biosyn Pros & Cons

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 34%
  • Company is almost debt free.

Cons

  • Debtor days have increased from 99.37 to 193.03days.
  • Stock is trading at 15.1 times its book value.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!